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One sentence summary: Exosome-like vesicles containing an active 20S proteasome 




Autoantibodies to components of apoptotic cells, such as anti-perlecan antibodies, 
contribute to rejection in organ transplant recipients. However, mechanisms of 
immunization to apoptotic components remain largely uncharacterized. Here, we used 
large-scale proteomics, with validation by electron microscopy and biochemical 
methods, to compare the protein profiles of apoptotic bodies and apoptotic exosome-
like vesicles, smaller extracellular vesicles released by endothelial cells downstream of 
caspase-3 activation. We identified apoptotic exosome-like vesicles as a central trigger 
for production of anti-perlecan antibodies and acceleration of rejection. Unlike apoptotic 
bodies, apoptotic exosome-like vesicles triggered the production of anti-perlecan 
antibodies in naïve mice and enhance anti-perlecan antibody production and allograft 
inflammation in mice transplanted with a MHC-incompatible aortic graft. The 20S 
proteasome core was active within apoptotic exosome-like vesicles and controlled their 
immunogenic activity. Finally, we showed that proteasome activity in circulating 
exosome-like vesicles increased following vascular injury in mice. These findings open 
new avenues for predicting and controlling maladaptive humoral responses to apoptotic 






Antibodies targeting the vasculature of solid allografts are major risk factors of poor 
outcomes in solid organ transplantation (1-7). Although donor specific anti-human 
leucocyte antigen antibodies (DSA) play a major role in allograft vascular injury, 
autoantibodies are increasingly recognized as important contributors to allograft 
vascular rejection and decreased long-term survival (8-19). Autoantibodies to vimentin, 
angiotensin II type 1 receptor, collagen V, tubulin, fibronectin and perlecan/LG3 have 
been associated with increased rejection rates and reduced survival of heart, kidney 
and lung allografts (8, 17, 20-28). The classic view in the field was that autoantibody 
titers increase during acute rejection episodes secondary to the release of danger 
associated molecular patterns (DAMPs). However, recent studies have reported the 
presence of autoantibodies prior to transplantation in de novo transplant patients, 
excluding rejection as a sine qua non factor for production of auto-antibodies (8). Anti-
LG3 and anti-angiotensin receptors have been detected in untransfused*untransplanted 
males and untransfused*untransplanted females who have never been pregnant (8, 29), 
also suggesting that allo-sensitizing events are not required for their production (8, 17, 
20-25).  
 
Abnormal reactivity to apoptotic cells plays a role in fuelling the production of at least 
some of these autoantibodies. Two recent studies have identified circulating levels of 
IgG reactive with apoptotic cells as a marker of antibody-mediated rejection (ABMR) 
(30, 31) in renal transplant patients. Remarkably, the detection, pre-transplantation, of 
antibodies reactive with apoptotic cells predicted increased risk of ABMR and reduced 
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long-term allograft survival. Our group also described an association between pre-
transplantation titers of IgG autoantibodies against the C-terminal perlecan fragment 
LG3 and the risk of acute vascular rejection in renal transplant patients (8). Apoptosis of 
endothelial cells is a major pathway regulating perlecan proteolysis and production of 
LG3 (32, 33). The association between autoantibodies and apoptosis is intriguing, given 
the classical notion that apoptosis represents a non-immunogenic if not tolerogenic type 
of regulated cell death (34, 35). Apoptotic cells are known to release apoptotic bodies, 
which, when engulfed by professional phagocytes, trigger the secretion of anti-
inflammatory cytokines (e.g. TGF-β, IL-10) (34, 36) and increase numbers of regulatory 
T cells. Autoantibodies to components of apoptotic cells or apoptotic bodies have been 
identified in lupus patients (37), due to abnormalities in clearance of apoptotic cells that 
prevent phagocytosis-induced immune tolerance and lead to secondary necrosis (34). 
However, no propensity towards lupus or other autoimmune diseases was found in 
patients with autoantibodies against apoptotic cells or perlecan/LG3 (8, 30).   
 
Recent work by our group and others has highlighted a major role for apoptosis and 
caspase-3 activation in controlling the release of extracellular vesicles (EVs) that appear 
to differ from classical apoptotic bodies (38-40). Apoptotic bodies, classically ranging in 
size from 1-5 um and characterized by the presence of histone components, are 
released by apoptotic cells through caspase-dependent pathways (41). Caspase 
activation can also lead to the release of smaller EVs, referred to as apoptotic exosome-
like vesicles and ranging in size from 30 to 100 nm. The immune modulating functions 




Here we aim to evaluate the immunogenic potential of the various extracellular 
structures released by apoptotic cells (ECs) downstream of caspase-3 activation in the 
early phases of apoptosis. We use large scale proteomics to profile the protein 
signatures of apoptotic bodies and apoptotic exosome-like vesicles. In addition, we 
compare the capacity of apoptotic exosome-like vesicles and apoptotic bodies to trigger 
the production of autoantibodies in transplanted and non-transplanted mice and shape 





Apoptotic endothelial cells release different types of EVs downstream of caspase-3 
activation 
To characterize the various types of EVs released by apoptotic ECs, human umbilical 
vein endothelial cells (HUVECs) or primary murine aortic endothelial cells (mECs) were 
induced to undergo apoptosis through exposure to serum-free medium in vitro. In 
keeping with the translational scope of our work, we chose serum starvation for 
stimulation of apoptosis as exposure to serum free preservation solution before 
transplantation is an integral component of all types of organ transplantations. In both 
cell types, serum deprivation significantly increased caspase-3 activation and the 
percentage of cells with chromatin condensation in absence of cell membrane 
permeabilization (Supplementary figure 1a and b). These results are consistent with 
previous work by our group demonstrating that this system induces apoptosis in the 
absence of primary or secondary necrosis (39, 42). Preventing activation of caspases 
and, more specifically, caspase-3 through biochemical inhibition or the use of mECs 
from caspase-3 -/- mice significantly reduced the development of apoptosis 
(Supplementary figures 1a and 1b). Medium conditioned by serum-starved HUVEC or 
mEC was harvested at time points associated with caspase-3 activation and evaluated 
for the presence of EVs (Figures 1a and 1b). Using a high sensitivity flow cytometer 
equipped with a forward scatter coupled to a photomultiplier tube designed to resolve 
smaller particles (Supplementary Figure 2) (43, 44), we confirmed that vesicles of 
various sizes are released by endothelial cells during apoptosis (Figures 1a and 1b). 
The vast majority of detected particles (95-99%) were sensitive to dissolution by the 
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detergent Triton X-100, confirming that these structures are bound by a lipid membrane 
(Figures 1a, 1b and supplementary figure 3). 
 As previously published, serum starved ECs engage a mixed autophagic and apoptotic 
response without any necrosis (39, 42). Preventing autophagy through biochemical 
inhibition with bafilomycin A1 did not modulate the release of extracellular vesicles 
(Supplementary figure 4). However, pan-caspase inhibition, specific caspase-3 
inhibition or the use of endothelial cells from caspase-3 -/- mice led to a significantly 
reduced production of apoptotic exosome-like vesicles and to a lesser extend apoptotic 
bodies (Figures 1a and 1b) highlighting the importance of caspases in the secretion of 
EVs by serum starved ECs. 
 
We then used sequential centrifugation of conditioned medium to isolate fractions 
enriched in apoptotic bodies or apoptotic exosome-like vesicles. The two fractions 
showed EVs with distinct ultrastructural characteristics (Figure 1c and supplementary 
figure 5 and 6). As reported previously (42), the majority of EVs isolated by 
centrifugation at 50,000xg were within the range of apoptotic bodies from 1 to 5 um, 
(containing intracytoplasmic components and various organelles, such as mitochondria) 
along with some smaller membrane vesicles within microvesicle size range (between 
0.25 uM to 1 uM). (Figure 1c and supplementary Figure 5). The fraction isolated by 
centrifugation at 200,000xg was enriched in smaller EVs showing a heterogeneous 
population of membrane-bound vesicles ranging in size from 30 to 100 nm (Figure 1c 
and supplementary Figure 6). Collectively, these results demonstrate that EVs of 




Proteomics profiling of exosome-like vesicles and apoptotic bodies reveals distinct 
proteome signatures 
To further characterize the differences between EVs released by apoptotic ECs, we 
performed a large-scale proteomics analysis and profiled the abundance of proteins in 
apoptotic bodies and apoptotic exosome-like vesicles. Apoptotic bodies and exosome-
like vesicles were characterized by strikingly distinct protein markers (Figure 1d), 
confirming that exosome-like vesicles do not merely represent the debris of apoptotic 
bodies. Apoptotic bodies contain a higher number of proteins, with 546 identified 
proteins, while only 235 proteins were identified in exosome-like vesicles. The heatmap 
of protein abundance revealed that typical markers of apoptotic bodies such as histones 
(Histone H2A type 2-A. Histone H4 and Histone H2B type 2-E) were enriched in 
apoptotic bodies (Figure 1d).  
 
We then performed gene ontology analysis to gain further insights into the processes by 
which proteins and pathways are actively modulated in the different EV subsets 
(Supplementary Figure 7). In line with our previous findings (42), apoptotic bodies were 
found to be enriched in ribosomal proteins and proteins from the cytosol, endoplasmic 
reticulum, nucleus and mitochondria. Exosome-like vesicles were enriched in 
extracellular matrix, basement membrane proteins and several lysosomal proteins 
(Supplementary Figure 7). More than 80% of the exosome-like vesicle proteome was 
listed in Exocarta and Vesiclepedia databases (Supplementary figure 8a and 8b) Also, 
62% of the top 50 exosome protein markers according to Exocarta database were 
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identified in exosome-like vesicles (Supplementary Table 1). Furthermore, western blot 
analyses comparing protein profiles of apoptotic bodies and apoptotic exosome-like 
vesicles showed enrichment in the exosome markers synthenin, fibronectin and TCTP 
(Supplementary figure 8c). Apoptotic bodies did not express characteristic exosome 
markers but showed increased expression of GM130 and tubulin. However, some 
classical exosome markers such as CD9, CD81, and TSG101 were not expressed in 
apoptotic exosome-like vesicles, as evidenced by proteomic analysis or western 
blotting, suggesting that these membrane vesicles, although closely related to 
exosomes, present some differences within protein signatures (Supplementary figure 8). 
Interestingly, the functions of proteins exclusive to exosome-like vesicles were 
associated with proteasomal degradation and ligase activities, while those of apoptotic 
bodies were enriched for RNA processing and vesicle targeting. More detailed analyses 
identified perlecan as one of the basement membrane proteins present in apoptotic 
exosome-like vesicles (Figure 1d and supplementary figure 7), with higher sequence 
coverage of the LG3 fragment of perlecan in exosome-like vesicles compared with 
apoptotic bodies (Figure 2a and supplementary Figure 9). Since LG3 and antibodies to 
LG3 have been associated with rejection in animal models and transplant patients (8, 
45-47), we used electron microscopy with immunogold-labelling to further characterize 
the presence of LG3 in preparations of apoptotic exosome-like vesicles. Immunogold 
labelling identified LG3 in vesicular structures ranging in size from 30 to 100 nm (Figure 
2b). To confirm that LG3 is released through caspase-dependent pathways, we 
assessed LG3 levels in preparations of exosome-like vesicles from caspase-inhibited or 
caspase 3-/- ECs. Pan-caspase inhibition or the use of caspase-3 -/- ECs significantly 
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reduced release of LG3 (Figures 2c and 2d). Collectively, these results demonstrate 
that apoptotic bodies and apoptotic exosome-like vesicles are characterized by distinct 
protein markers and that LG3 is a marker of apoptotic exosome-like vesicles.  
 
Apoptotic exosome-like vesicles trigger anti-LG3 production. 
 
We then evaluated whether apoptotic exosome-like vesicles can trigger the production 
of anti-LG3 autoantibodies and shape the severity of rejection. We first evaluated 
whether intravenous injection of apoptotic exosome-like vesicles fosters the production 
of anti-LG3 antibodies in wild-type naïve mice. Sequential centrifugation was used to 
purify apoptotic bodies and apoptotic vesicles from serum-free medium conditioned by 
1x104 murine apoptotic ECs. Each fraction was then resuspended in half the initial 
volume of conditioned medium and injected to mice intravenously every other day for 
three weeks. Injection of apoptotic exosome-like vesicles but not apoptotic bodies 
significantly increased the production of anti-LG3 IgG antibodies in naïve mice (Figure 
2e). Since total protein levels were found to be six times lower in preparations of 
apoptotic bodies compared with preparations of apoptotic exosome-like vesicles (2 
ug/mL and 0.3 ug/mL, respectively), we also evaluated whether increasing the amount 
of injected apoptotic bodies would trigger the production of anti-LG3 antibodies. 
Injecting equal amounts of proteins from preparations of apoptotic bodies and 
preparations of apoptotic exosome-like vesicles failed to unmask immunogenic activity 




We then evaluated whether the injection of apoptotic exosome-like vesicles increases 
the production of other autoantibodies and markers of B cell activation. Anti-nuclear 
antibody (ANA) titers were increased in mice injected with exosome-like vesicles 
compared with apoptotic bodies or control mice (Supplementary figure 11a). Enhanced 
numbers of germinal centre B cells and follicular helper T cells were observed in mice 
injected with exosome-like vesicles (Supplementary figures 11b, 11c 11d and 11e). 
Collectively, these data suggest that apoptotic exosome-like vesicles, unlike apoptotic 
bodies, favor B cell responses associated, at least in part, with the production of 
autoantibodies. 
 
Apoptotic exosome-like vesicles aggravate vascular rejection  
 
We then compared the impact of apoptotic exosome-like vesicles and apoptotic bodies 
on the production of anti-LG3 antibodies and the severity of rejection in allografted mice. 
Apoptotic bodies and apoptotic exosome-like vesicles were purified from serum-free 
medium conditioned by 1x104 murine EC and injected intravenously every other day for 
three weeks post-transplantation into recipients of a fully MHC-mismatched aortic graft. 
Since we aimed to evaluate aggravation of rejection, allografts were studied at three 
weeks post-transplantation, a time point normally associated with minimal vascular 
remodelling and inflammation (Supplementary figure 12) (46, 47). The injection of 
transplanted mice with apoptotic exosome-like vesicles, but not apoptotic bodies, 
significantly increased the production of anti-LG3 IgG antibodies (Figure 3a) and 




Infiltration by CD3+ T cells and CD20+ B cells was significantly increased in mice 
injected with apoptotic exosome-like vesicles but not with apoptotic bodies (Figures 3b, 
3d and 3e). C4d deposition, a hallmark of immune complex deposition, was also 
increased in mice injected with apoptotic exosome-like vesicles (Figures 3b and 3f). 
Donor specific antibodies (DSAs) were detected in allografted mice but their levels were 
not affected by the injection of exosome-like vesicles or apoptotic bodies (Figure 3g). 
This suggests that apoptotic exosome-like vesicles accelerate rejection through immune 
complex-dependent but DSA-independent pathways. Anti-LG3 antibodies produced 
secondary to injection of apoptotic exosome-like vesicles are mainly of complement-
fixing isotypes (Supplementary figure 13). Collectively, these results demonstrate that 
apoptotic exosome-like vesicles, unlike apoptotic bodies, aggravate vascular allograft 




The proteasome core complex is enriched and active in apoptotic exosome-like vesicles 
 
The observation that exosome-like vesicles induce the production of anti-LG3 
antibodies both in grafted and naïve mice prompted us to further analyze their protein 
signature. Intriguingly, we observed a strong enrichment for the proteasome core 
complex specifically in apoptotic exosome-like vesicles (Figures 4a and 4b). In our 
proteomics dataset, all the catalytic subunits of the 20S proteasome core were identified 
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with high confidence in the exosome-like vesicles, while these proteins were absent in 
apoptotic bodies (Figures 4a and 4b). Western blot analysis further confirmed the 
presence of the alpha-3 subunit of the proteasome specifically in exosome-like vesicles 
(Figure 4a). In contrast, only 4 proteasome-associated proteins were identified in 
apoptotic bodies, all contained within the 19S regulatory subunit. Immunogold labelling 
for the 20S proteasome identified immunoreactivity in EVs of 30-100 nm in size (Figure 
4c).  
 
Quantitative proteomics based on spectral count indicated comparable levels of all three 
catalytic subunits containing chymotrypsin-like (5), trypsin-like (2) and caspase-like 
(1) activities in exosome-like vesicles (Supplementary Table 1). However, we detected 
several trypsin inhibitors (serpins) in our dataset (Supplementary Table 1). Notably, 
inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2) is exclusively found in exosome-like 
vesicles. SERPINE1 (plasminogen activator inhibitor 1) is also enriched in exosome-like 
vesicles while it is essentially absent in apoptotic bodies. The presence of inhibitors of 
specific enzymatic activities in the exosome-like vesicles could result in a dynamic 
modulation of the proteasome activity. Thus, we evaluated whether proteasome activity 
was present in the various fractions. Consistent with our proteomics findings, we found 
enhanced caspase-like activity/ug of total proteins in the apoptotic exosome-like vesicle 
fraction compared to apoptotic bodies and parent cells (Figure 4d). The enhancement of 
caspase-like activity over other proteolytic functions of the proteasome correlated with 
the identification of trypsin and chymotrypsin inhibitors in the apoptotic nanovesicle 




To evaluate whether the presence of active proteasome is a major characteristic of 
apoptotic exosome-like vesicle, we evaluated if healthy endothelial cells could also 
secrete membrane vesicles containing active 20S proteasome. To avoid contamination 
of culture medium by membrane vesicles derived from fetal bovine serum (FBS), we 
generated vesicle free normal medium using FBS spun at 200,000xg before its addition 
to culture medium (Supplementary figure 14a). Endothelial cells were exposed to 
normal culture medium for 4 hours. Small particle flow-cytometry demonstrated the 
presence of exosome-size membrane vesicles in medium conditioned by healthy cells 
(Supplementary figure 14b). In comparing by western blot equal amounts of membrane 
vesicles produced by normal or serum starved apoptotic endothelial cells and isolated 
by centrifugation at 200,000xg, we found that the exosome markers fibronectin, 
synthenin and TCTP were present in both conditions (Supplementary figure 14 d). 
However, the 20S proteasome core complex and caspase-like proteasome activity were 
detected exclusively in membrane vesicles released by serum starved apoptotic 
endothelial cells (Supplementary figure 14 c and d). These results support the notions 
that active 20S proteasome is secreted within exosome-like vesicles specifically under 
pro-apoptotic serum starved conditions. 
 
We than investigated if the presence of an active proteasomal core complex in apoptotic 
exosome-like is specific to apoptotic endothelial cell-derived vesicles. To this end we 
evaluated preparations of apoptotic exosome-like vesicles from medium conditioned by 
serum starved vascular smooth muscle cells and tubular epithelial cells undergoing 
15 
 
similar levels of apoptosis as serum starved endothelial cells (Supplementary figure 15a 
and 15b). Preparations from both cell types highlighted the presence of the 20S 
proteasome core complex by Western blot analysis as well as proteasome activity 
(Supplementary figure 15c and 15d), demonstrating that the presence of an active 
proteasome core complex is not exclusive to endothelial apoptotic exosome-like 
vesicles.  
 
To investigate whether the activity of the proteasome modulates the release and 
immunogenic activity of apoptotic exosome-like vesicles, we exposed ECs to 
bortezomib, a proteasome inhibitor, during serum starvation. Proteasome inhibition 
neither modulated endothelial apoptosis (Supplementary figure 16) nor prevented the 
production of EVs but dramatically reduced caspase-like activity in exosome-like 
vesicles (Figures 4e and 4f). We also performed large-scale proteomics on purified 
apoptotic exosome-like vesicles from bortezomib- or vehicle-treated apoptotic 
endothelial cells. Bortezomib treatment strongly modulated the protein content of 
exosome-like vesicles and increased the number of proteins identified (Figure 4g). 
Proteasome inhibition resulted in the enrichment of LG3 within exosome-like vesicles 
suggesting that LG3 is a proteasome substrate (Figure 4h). While 154 proteins were 
found in control exosome-like vesicles, 337 proteins were identified in bortezomib-
treated exosome-like vesicles (Supplementary Table 2). Also, 198 proteins were 
detected exclusively in exosome-like vesicles from bortezomib-treated cells, suggesting 
an important role for the proteasome in the degradation of vesicle proteins 
(Supplementary Table 2). Proteasomal degradation occurs in an ubiquitin-dependent 
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manner. We therefore identified ubiquitylated proteins by mass spectrometry. 
Proteasome inhibition with bortezomib resulted in the accumulation of ubiquitylated 
proteins in exosome-like vesicles (Figure 4i). Upon bortezomib treatment, 20 
ubiquitylation sites on 19 proteins were detected in nanovesicle extracts, while 
exosome-like vesicles produced in vehicle-treated serum starved cells showed only 5 
ubiquitylation sites on 5 proteins (Supplementary Table 3). Collectively these results 
support the notion that the proteasome, active within apoptotic exosome-like vesicles, 
regulates the processing of various proteins, including LG3. 
 
Proteasome activity is required for induction of anti-LG3 production and aggravation of 
allograft inflammation  
 
Since LG3 behaves as a proteasome substrate, we investigated the possibility that the 
proteasome-activity of apoptotic exosome-like vesicles regulates their capacity to 
induce the production of anti-LG3 autoantibodies. Both allografted and non-grafted mice 
were injected with an equal number of apoptotic exosome-like vesicles purified from 
either bortezomib-treated serum-starved endothelial cells or control vehicle-treated 
serum-starved endothelial cells. Naïve and transplanted mice exposed to apoptotic 
exosome-like vesicles from bortezomib-treated cells showed reduced levels of anti-LG3 
antibodies when compared to control exosome-like vesicles (Figure 5a). In transplanted 
mice, neointimal remodelling was similar in mice injected with exosome-like vesicles 
from bortezomib-treated cells or control apoptotic cells (Figure 5b). Allograft infiltration 
by CD3+ T cells and CD20+ B cells and C4d deposition however were significantly 
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decreased in mice injected with apoptotic exosome-like vesicles from bortezomib-
treated cells (Figures 5b, 5c and 5d). Collectively, these results suggest that 
proteasome activity within apoptotic exosome-like vesicles regulates anti-LG3 auto-
antibody formation and allograft inflammation.  
 
Vascular injury increases proteasome-activity in circulating exosome-like vesicles and 
triggers anti-LG3 production in vivo 
We then evaluated whether this pathway is recapitulated in vivo following vascular 
injury. We first focussed on renal artery clamping, a model of acute kidney injury (AKI), 
associated with increased caspase-3 activation within the renal microvasculature (48-
51). We chose this model because anti-LG3 antibodies have been found in renal 
disease patients awaiting a kidney transplant and AKI is common in these patients and 
predicts progressive renal dysfunction (52). In this model, renal function was reduced up 
to 7 days post-IRI (Figures 6a and 6b). The 20S proteasome core complex was 
identified within circulating exosome-like vesicles purified from mouse serum 2 days 
post-AKI by immunogold-labelling but was absent from exosome-size circulating 
vesicles purified from normal mice serum (Figure 6g and Supplementary figure 17). 
Moreover, both proteasome caspase-like activity and LG3 levels increased in exosome-
like vesicles preparations after AKI (Figures 6c, 6e and 6f). Anti-LG3 IgG antibodies 
titers increased significantly 7 and 14 days post-surgery and returned to baseline at 21 
days (Figure 6d).  
We studied a second model of vascular injury evoked by femoral arteriectomy leading to 
hind-limb ischemia (Figure 7a), taking into consideration the prevalence of severe 
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peripheral vascular disease in the end-stage renal disease population. Again, 
proteasome caspase-like activity and LG3 levels in circulating exosome-like vesicles 
increased significantly post-femoral arteriectomy (Figures 7b, 7c and 7d). Anti-LG3 IgG 
titers also increased significantly at 7 days post-surgery and remained elevated for up to 
21 days (Figure 7e). Collectively, these results demonstrate that vascular injury in vivo 
leads to enhanced caspase-like proteasome activity in circulating exosome-like vesicles 






Apoptosis is classically considered an anti-inflammatory and tolerogenic type of cell 
death (34). Mounting evidence, however, shows that the presence of autoantibodies 
reactive with components of apoptotic cells prior to solid organ transplantation predicts 
reduced allograft survival and risk of rejection (8, 13, 18, 19, 30). The present study 
identifies apoptotic exosome-like vesicles as a novel and immunogenic component of 
the paracrine apoptotic response. Using electron microscopy, unbiased proteomics and 
functional studies, we show that nanoscale extracellular vesicles released by apoptotic 
cells display immune-mediating functions distinct from apoptotic bodies. Apoptotic 
exosome-like vesicles induce B-cell responses in naïve and transplanted mice leading 
to the production of autoantibodies. Apoptotic exosome-like vesicles, but not classic 
apoptotic bodies, aggravate vascular rejection, with increased allograft infiltration by 
CD3+ T cells and CD20+ B cells, C4d deposition and vascular remodelling. C4d 
deposition induced by exosome-like vesicles is likely dependent on non-HLA-antibodies, 
as exosome-like vesicles did not modulate levels of anti-HLA antibodies in rejecting 
mice and triggered the production of complement-fixing autoantibodies such as anti-
LG3, known to promote C4d deposition (8).   
 
Our results highlight the complexity of paracrine signals released by apoptotic cells 
downstream of caspase-3 activation, with the concomitant release of tolerogenic and 
immunogenic signals. Unbiased comparative proteomic analysis established that 
different and almost mutually exclusive sets of proteins are present in apoptotic bodies 
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and apoptotic exosome-like vesicles, suggesting that their generation requires 
differential sorting of proteins and that their biogenesis is likely different. While it is well 
documented that caspase-3 activation regulates the generation of apoptotic bodies by 
plasma membrane blebbing (53), our results propose an important role for caspase-3 
activation in the release of apoptotic exosome-like vesicles. Although the precise 
molecular components regulating differential sorting of proteins into either apoptotic 
bodies or exosome-like vesicles is unclear, the present results suggest that distinct 
molecular pathways activated downstream of activated caspase-3 lead to the 
production of either apoptotic bodies or apoptotic exosome-like vesicles. Whether 
nanovesicles are shed from the plasma membrane, generated by exocytosis of Multi 
Vesicular Bodies (MVB) in a caspase-dependent manner or by another mechanism still 
remains to be determined. We showed in previous work that serum starvation leads to 
the accumulation of multivesicular structures (39) but the link between with the 
biogenesis of apoptotic exosome-like nanovesicles and MVBs requires further 
investigations. Apoptotic exosome-like vesicles were found to express a protein 
signature that is both closely related yet distinct from classical exosomes. The presence 
and absence of different sets of proteins have been suggested as minimal requirements 
to characterize extracellular vesicles (54). Transmembrane or lipid-bound extracellular 
proteins (such as CD9, CD63, CD81, integrins, cell adhesion molecules, growth factor 
receptors, heterotrimeric G proteins, MFG-E8) and cytosolic proteins (TSG-101, 
annexins, Rabs, syntenin) and the under-representation of endoplasmic reticulum, 
Golgi, mitochondrial and nuclear proteins are considered characteristic of exosomes 
(54). Our proteomics data identified integrins (ITGA5, ITGB1), adhesion molecules  
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(MCAM), annexins (ANXA1, ANXA2, ANX5) and syntenin in our preparations and 
confirmed the under-representation of ER, Golgi, mitochondrial and nuclear proteins 
suggesting that small vesicles released by apoptotic cells display typical characteristics 
of exosomes. Our results also highlighted some distinctive feature such as release 
through caspase-3-dependent pathways and the presence of an active proteasome 
core complex in small vesicles released by apoptotic cells, hence our choice to refer to 
them as «apoptotic exosome-like» vesicles and not as classical exosomes.  
 
One of the most striking observations of this study is the identification of proteasome 
activity in endothelial exosome-like vesicles.  In eukaryotic cells, proteasomes are highly 
conserved protease complexes typically composed of the 19S regulatory cap and the 
20S proteolytic core. The proteasomal degradation pathway is essential for many 
cellular processes, including the cell cycle, the regulation of gene expression, and 
antigenic presentation. In humans, extracellular proteasomes have been found 
circulating in the plasma of patients suffering from a variety of inflammatory, 
autoimmune and neoplastic diseases (55-60) and, in various conditions, the 
concentration of circulating proteasomes correlates with disease activity (61). The 
presence of circulating proteasome is intriguing since proteasomal subunits do not 
contain signal sequence for export via the classic secretory pathway, which argues for 
an alternative secretion mechanism. The release of proteasome in the extracellular 
milieu as a result of membrane disruption is proposed and cannot be excluded, but the 
present results and other studies support the existence of regulated mechanisms. The 
release of active 20S proteasome has also been described recently in EVs originating 
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from other cell types such as T cells (shedding microparticles) (62) and mesenchymal 
stem cells (in exosomes derived from the endosomal compartment) (63). Here we 
demonstrate that the release of active proteasome within exosome-like vesicles is 
occurs in association with cell stress and stimulation of apoptotic as healthy endothelial 
cells do not secrete active proteasome within membrane vesicles. However the 
secretion of the proteasome core complex in apoptotic vesicles is not specific to 
endothelial cells as we found the presence and activity of the proteasome in 
nanovesicles produced by other cell type undergoing apoptosis such as vascular 
smooth muscle cells and tubular epithelial cells, suggesting that this pathway is likely 
applicable to various disease states associated with apoptotic cell death.  
 
 
 Our results also show that proteasome activity within apoptotic exosome-like 
vesicles is one of the key determinants of their immunogenicity. Inhibiting proteasome 
activity in parent apoptotic endothelial cells did not modulate cell death and the release 
of apoptotic exosome-like vesicles but completely abrogated all proteasome activity in 
exosome-like vesicles. Injection of exosome-like vesicles with inhibited proteasome 
activity elicit significantly less anti-perlecan/LG3 production when injected in naïve mice. 
Injection of these vesicles in transplanted animals also resulted in reduced levels of 
anti-LG3 antibodies as well as lower numbers of graft infiltrating T and B cells and 
reduced C4d deposition. Reduced anti-perlecan/LG3 production occurs in spite of 
higher levels of perlecan/LG3 in proteasome-inhibited vesicles, demonstrating that 
failure to trigger an antibody-response is not caused by lower levels of the immunogen. 
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Although the detailed characterization of the specific molecular components regulating 
perlecan/LG3 immunogenicity by the active proteasome core within exosome-like 
vesicles will require further investigation, our results demonstrate that proteasome 
activity within these vesicles is central to induction of anti-perlecan/LG3 production in 
vivo. Bortezomib is currently being used in the treatment of refractory antibody-
mediated rejection as a B cell-depleting agent based on its pro-apoptotic activity on 
plasma cells and B cells (64, 65). The present results add further insights into additional 
pathways of potential importance in the anti-rejection activity of bortezomib. By lowering 
the immunogenicity of exosome-like vesicles produced at sites of vascular injury, 
bortezomib could prevent the formation of autoantibodies that further accelerate 
leukocyte infiltration and complement deposition. The proteasome activity of exosome-
like vesicles was, however, dispensable for acceleration of neointima formation. Various 
factors could explain this finding. The perlecan fragment LG3 per se acts as a pro-
migration factor on mesenchymal stem cells and smooth muscle cells thus promoting 
their accumulation of sites of vascular injury (46, 47) and perlecan fragments have also 
been reported to bind TLR 2 and 4 (66). Other proteins and mediators present in 
exosome-like vesicles such as tissue degrading enzymes (metalloproteinases 2 and 9), 
DAMPs/ TLR ligands (heat shock proteins 75, 10, 71, 70 and fibronectin) and PAI-1 
(SERPINE1), could also potentially accelerate the fibroproliferative and inflammatory 
responses of the vessel wall. Moreover, studying the nucleic acid and lipid content of 
these exosome-like vesicles might offer additional insights into mechanisms induced by 




Humoral immune responses against perlecan have been found to be associated with 
rejection in several human transplant cohorts and in animal models of acute and chronic 
allograft rejection (8, 21, 67, 68). In all these settings, I/R injury have been suspected to 
play a role in anti-perlecan autoimmune responses. Since anti-perlecan antibodies have 
been described prior to transplantation in patients without autoimmune conditions (29), 
we evaluated whether episodes of vascular injury, which are common in renal disease 
patients, could be associated with increased circulating levels of markers characteristic 
of apoptotic exosome-like vesicles. Two models of vascular injury in mice led to 
increased caspase-like activity and LG3 levels in circulating exosome-like vesicles 
followed by elevated anti-LG3 IgG levels, confirming a close association between 
vascular and/or tissue injury, release of immunogenic exosome-like vesicles and 
production of anti-LG3.   
 
Our study has however a number of limitations. First, the biogenesis of apoptotic 
exosome-like vesicles remains incompletely understood. The abundance of exosomal 
markers suggests that inward budding of multivesicular bodies could be contributing to 
their biogenesis, yet how caspase-3 impacts intracellular trafficking and membrane 
fusion events leading to their release will require further investigation. Second, although 
we have showed that circulating levels of proteasome-labeled vesicles increase after 
renal ischemia-reperfusion injury and that proteasome caspase-like activity is increased 
in these vesicle preparations, we cannot determine precisely the cellular origin of these 
vesicles. Endothelial cells, vascular smooth muscle cells and tubular epithelial cells all 
release proteasome-active vesicles when injured in vitro. These cell types are targets of 
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injury during ischemia/reperfusion and could all be contributing to the release of 
apoptotic exosome-like vesicles in vivo. Further studies will be required to identify cell-
type specific markers of apoptotic exosome-like vesicles. Finally, we have demonstrated 
that exosome-like vesicles accelerate vascular rejection without increasing the 
production of donor-specific alloantibodies but rather by triggering the formation of 
humoral auto-immune pathways. The current study focused primarily on the protein 
composition of exosome-like vesicles and apoptotic bodies, and enabled the 
identification of source proteins from which could be derived antigenic peptides. It is 
also possible that these vesicles may contain small peptides from proteasome 
degradation that remained elusive to the current proteomics approach. The identification 
of these peptides and of specific perlecan-derived MHC class I or class II epitopes will 
require alternate methods that facilitate their recovery and further characterization by 
MS/MS sequencing to account for the diversity of the corresponding degradation 
products. This will be the subject of future investigations. 
 
Collectively, these results support the notion that vascular injury in association with 
renal injury prior to transplantation, leads to increased circulating proteasome activity 
within exosome-like vesicles fractions, therefore increasing sensitization to 
autoantigens. By providing novel insights into pathways responsible for the production 
of autoantibodies prior to transplantation, these results suggest that assessment of 
proteasome activity within circulating apoptotic exosome-like vesicles before and at the 
time of transplantation represents new avenues for predicting and controlling 
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maladaptive humoral responses to apoptotic cell components that enhance risk of 




Materials and Methods 
 
Study design 
The aim of this study was to evaluate the immunogenic potential of the various 
extracellular structures released by apoptotic endothelial cells. We use large scale 
proteomics to profile the protein signatures of apoptotic bodies and apoptotic exosome-
like vesicles generated in vitro. We then compared the capacity of apoptotic exosome-
like vesicles and apoptotic bodies to trigger the production of autoantibodies in 
transplanted and non-transplanted mice and shape the severity of rejection. The 
observation that exosome-like vesicles induced the production of anti-LG3 antibodies 
both in grafted and naïve mice prompted us to further analyze their protein signature. 
We found a strong enrichment and activity of the 20S proteasome core complex in 
apoptotic exosome-like vesicles by proteomic analyses, immunoblots and electron 
microscopy. We next investigated, using inhibition of proteasome activity with 
bortezomib, whether the activity of the proteasome modulates the release and 
immunogenic activity of apoptotic exosome-like vesicles in vitro and in vivo. Finally, 
using in vivo models of vascular injury, we evaluated whether the release of 
proteasome-active exosome-like vesicles occurs in vivo following vascular injury. Group 
sizes were selected on the basis of our experience with these systems. Mice were age- 
and sex-matched between groups. Investigators were not blinded when conducting and 
evaluating the experiments, and no randomization was necessary. No data were 
excluded from this study. 
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Cell culture and conditioned medium preparation 
Endothelial cells  
Murine EC (mEC) were isolated from the aorta of C57BL/6 mice grown in DMEM low 
glucose culture media supplemented with endothelial cell growth supplements (ECGS, 
Alfa Aesar ), 10% FBS (Invitrogen), 10% new born calf serum (Invitrogen), heparin 
(6300U, Sandoz), 1% penicillin-streptomycin and 1% fungizone. Human umbilical vein 
endothelial cells (HUVEC) were obtained from Clonetics and cultured in EGM-2MV 
complete medium (Clonetics). To generate conditioned medium, cells were exposed to 
serum free medium alone or in the presence of either pan-caspase inhibitor zVAD-fmk 
(100 Um; R&D system), caspase 3 and 7 inhibitor DEVD (50 uM;R&D systems), 
proteasome inhibitor bortezomib (100 ug/ml; Stressmarq) or its vehicle DMSO for 4 h 
(HUVECS) or 9 h (mEC). In previous work, we demonstrated that this system leads to 
the release of active mediators by apoptotic ECs downstream of caspase-3 activation 
without cell membrane permeabilization (40).  
Human proximal tubular epithelial cells  
Human proximal tubular epithelial cells (hTECs) were isolated as previously described 
from non-diseased nephrectomy samples from patients with renal cell carcinoma (69). 
Briefly, cortical tissue from kidney samples were incubated with collagenase (Sigma) for 
1h and passed through a 70 uM cell strainer (Falcon). Cells were washed and 
resuspended in HPTC media (10% FBS (Sigma), 1% penicillin-streptomycin (Sigma), 
1% hormone mix (Sigma), 25ng/mL human EGF (Sigma), 25mM HEPES(Sigma)) then 
plated on collagen IV coated plates and grown at 37 degrees Celsius in 5% CO2. HPTC 
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were washed and the media was changed the following day. To generate conditioned 
medium, cells were exposed to serum free medium for 24 h. 
Vascular smooth muscle cells  
A7R5 cells (rVSMC) (American Type Culture Collection) were cultured in Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12 supplemented with 10% fetal bovine 
serum (FBS; Invitrogen). To generate conditioned medium, cells were exposed to 
serum free medium for 48 h. 
 
 
Screening for apoptosis by fluorescence microscopy 
Fluorescence microscopy of unfixed/unpermeabilized adherent cells stained with 
Hoechst 33342 (20-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2.50-bi-1-1H-
benzimidazole) (HT) and propidium iodide (PI) was performed as previously described 
(42). 
   
Immunoblotting 
Proteins were extracted, separated by electrophoresis, transferred to nitrocellulose 
membranes or PVDF (for caspase 3 detection), and probed. Antibodies used for 
Western blotting were: antibodies against perlecan (Santa Cruz), 20S proteasome alpha 
3 (Santa-Cruz), CD63 (Abcam), GM130 (Abcam), tubulin (Calbiochem), Syntenin-1 
(Santa Cruz), TCTP (Santa Cruz) and fibronectin (Abcam).   
 
Flow cytometry analyses of EVs  
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The flow cytometry analyses were done as previously described in Rousseau et al. (70). 
In short, fluorescence was used as trigger signal and positive fluorescent events were 
plotted on an SSC/FSC-PMT graph. The nanovesicle gate of detection was determined 
based on the acquisition of Sky blue and yellow-green microspheres of 90, 450, 840, 
1000 and 3200 nm (Supplementary Figure 1) and 1000 microspheres were acquired. 
Conditioned media were labeled for 30 min with V450 probe-conjugated Annexin-V, 
diluted 1:50, (BD bioscience) at room temperature in the dark. Since annexin-V 
recognizes PS in a calcium dependent manner, we confirmed its specific recognition of 
EVs by chelating Ca2+ ions using samples detection in presence of 50 µM EDTA as a 
baseline (70). To process the data quantitatively, a known number of polystyrene 
microspheres (15 um diameter; Polysciences, PA, USA) were added to each tube as 
already described (70). To confirm that events detected were genuine extracellular 





Preparation of fractions enriched in apoptotic bodies or apoptotic exosome-like 
vesicles  
Serum-free media conditioned by HUVECs were fractionated using sequential 
centrifugation: a first centrifugation at 1200xg for 15 min at 4ºC to pellet cell debris; a 
second centrifugation at 50 000 x g for 15 min at 4ºC to pellet apoptotic bodies and a 
final ultracentrifugation (200 000xg for 18 h at 4ºC) to pellet exosome-like vesicles. 
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Pellets containing either apoptotic bodies or exosome-like vesicles were resuspended in 
half the initial volume of conditioned medium. For chronic exposure to the different 
apoptotic vesicles, a volume of 150ul of either exosome-like vesicles or apoptotic bodies 
preparation or vehicle (PBS) was injected i.v. (caudal vein) every second day up to 8 
injections in the different animal models used (see animal section below).  
 
Proteasome activity assay 
The proteasome activity assay was performed in white 96 wells plates using the 
Proteasome-GloTM chymotrypsin-like, trypsin-Like and caspase-Like Cell-Based 
Assays (Promega) in accordance with the manufacturer’s instructions using cells lysate 
(0.4 ug), exosome-like vesicles (0.4 ug) or apoptotic bodies from HUVEC supernatant 
(0.4 µg) or exosome-like vesicles purified from mouse serum (50ug).  Luminescence 
was measured using a Perkin Elmer Victor 3 V 1420 MultilabelCounter 1420-040 
Microplate Reader.  
 
Electron microscopy  
Apoptotic bodies  
The fraction enriched in apoptotic bodies was fixed in 2% glutaraldehyde-0.1M sodium 
cacodylate, post-fixed in 1% OsO4, dehydrated in alcohol, processed for flat embedding 
in Epon 812 and observed at the Zeiss CEM 902 electron microscope, as previously 
described (71).  
Exosome-like vesicles  
32 
 
Preparations of exosome-like vesicles were fixed in 4% paraformaldehyde in PBS buffer 
and were either, contrasted and embedded for whole-mount EM observation or 
processed for immunolabelling. Fixed exosome-like vesicles (5 uL) were deposit on a 
Formvar/carbon coated grid for 20 min and washed on drops of PBS at RT. The grid 
was then directly processed for negative staining or immunolabeling. Negative staining:  
The grid was transferred onto a drop of 1% glutaraldehyde for 5 min and washed on 
several drops of water. Contrasting was performed by transferring the grid onto a drop 
of 2% uranyl acetate-0.075 M oxalate pH7 solution for 5 min. Finally the grid was 
transferred onto a drop of 2% methyl cellulose-4 % uranyl acetate (9:1) solution for 10 
min on ice and excess solution was blotted with Whatman filter paper and air dried. 
Examination was performed with a Philips CM100 electron microscope. 
Immunolabeling: The grid was blocked by incubating in 50mM glycine in PBS for 15 min 
then  transferred onto 1% ovalbumin in PBS for 10min. The grid was incubated for 30 
min on a drop of rabbit anti-LG3 antibody or rabbit anti-proteasome antibody, both 
diluted at 1:50 in PBS (Santa Cruz Biotechnology, Inc.), and washed on several drops 
of PBS. Finally, the grid was incubated on a drop of anti-rabbit IgG conjugated to 10 nm 
gold particles for 20 min, washed with PBS and processed for negative staining.   
 
Proteomic analysis of purified exosome-like vesicles  
SDS-PAGE and mass spectrometry 
Proteins (20 ug) were separated on a 4-12% pre-cast NuPAGE gel (Invitrogen). The gel 
was Coomassie stained, the lanes were cut into pieces, reduced with dithiothreitol 
(DTT; Sigma Aldrich) and alkylated by Chloroacetamide (Sigma-Aldrich). The gel pieces 
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were then digested by trypsin and peptides extracted three times with 90% acetonitrile 
(ACN)/0.5 M Urea. Combined extracts were desalted with ZipTips (Millipore), dried and 
re-suspended in 5% ACN, 0.2% Formic acid (FA) for mass spectrometry analyses. 
Peptides were separated on a 150 µm ID, 15 cm reversed phase nano-LC column 
(Jupiter C18, 3 μm, 300 Å, Phenomex) with a loading buffer of 0.2% formic acid (FA). 
Peptide elution was achieved by a gradient of 5-40% ACN in 85 min on an Eksigent 2D-
nanoLC (Dublin, CA) operating at a flow-rate of 600 nL/min. The nano-LC was coupled 
to a LTQ-Orbitrap Elite mass spectrometer (Thermo-Electron) and samples were 
injected in an interleaved manner. The mass spectrometer was operated in a data-
dependent acquisition mode with a 1-s survey scan at 120 000 resolution, followed by 
12 product ion scans (MS/MS) of the most abundant precursors above a threshold of 
10,000 counts in the LTQ part of the instrument. CID was performed in the LTQ at 35% 
collision energy and an Activation Q of 0.25. For each mass spectrometry-based 
proteomics experiment three independent biological replicates were used in triplicates.  
 
 
Protein Identification and data analysis 
The centroided MS/MS data were merged into single peak-list files (Distiller, v2.4.2.0) 
and searched with the Mascot search engine v2.3.01 (Matrix Science) against the 
forward and reversed IPI human v3.54 database. Mascot was searched with a parent 
ion tolerance of 0.05 Da and a fragment ion mass tolerance of 0.5 Da. 
Carbamidomethylation of cysteine, oxidation of methionione, deamidation and 
phosphorylation of serine, threonine and tyrosine residues (and ubiquitylation of lysine 
34 
 
residues (GlyGly) were specified as variable modifications. Proteins were considered 
identified when they had at least 2 different peptide identifications and the combined 
score of unique peptide identifications exceeded the score of the first reversed-
database hit reaching 2%. This resulted in a false-discovery rate of <2 % on the peptide 
level. Relative protein abundance was determined using a redundant peptide counting 
approach (spectral counts). The value of redundant peptide counts from three 





Gene Ontology (GO) annotations for cellular component, biological process and 
molecular function were obtained from the Gene Ontology project using the DAVID 
Bioinformatics resources (http://david.abcc.ncifcrf.gov/) (72, 73). To identify GO terms 
that were statistically over represented in our protein list, we used the binomial statistics 
tool to compare classifications of multiple clusters of lists to a reference list (Homo 
sapiens total proteome). Only terms that were significantly enriched/depleted with a p-
value <0.05 were used for the analysis.  
 
Animal studies 
Adult C57Bl/6 and BALB/c mice (20-22 g) (Charles River, St-Constant, QC) were 
maintained on a 12-hour light-dark cycle and fed a normal diet ad libitum. All 
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experiments on mice were approved by the CRCHUM’s Comité Institutionnel de 
Protection des Animaux (CIPA).  
 
Aorta transplantation procedures  
Mice were anaesthetized using isoflurane (2%) by inhalation. Aortic transplantation was 
erformed as described elsewhere with minor modifications.(74, 75). Briefly, 1 mL of 
heparinized saline (50 μL/mL) was injected into the vena cava to flush the aorta. A 6-
mm segment of abdominal aorta from below the renal arteries to just above the aortic 
bifurcation was excised and soaked in ice-cold 0.9% normal saline. When mentioned, 
warm ischemia was induced by clamping the aorta for 15 min before excision from the 
donor. The grafts were then excised and sutured orthotopically with end-to-end 
anastomoses using 11-0 nylon interrupted sutures. 
 
Renal ischemia reperfusion injury procedures  
Mice are anesthetized with isoflurane and buprenorphin (0.05 mg/kg/SC) and placed on 
a heated surgical table. After a midline incision, the left kidney was exposed and blood 
supply was interrupted by application of microvascular clamps on the renal artery. After 
30 min, the clamps were released, and reperfusion is visualized. The right kidney was 
than exposed and ligation of ureter and renal blood vessels with 4-0 suture was 
performed prior to right kidney nephrectomy. After surgery, analgesic was administered 
(dextrose 2.5%, 0.3mL).  
 
Murine ischemic hindlimb model 
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Unilateral hindlimb ischemia, a model of persistent vascular injury (76), was surgically 
induced in mice by femoral arteriectomy as previously described (77). Briefly, the 
animals were anesthetized with 2% isoflurane, after which an incision was made in the 
skin overlying the middle portion of the left hind limb. After ligation of the proximal end of 
the femoral artery, the distal portion of the saphenous artery was ligated, and the artery 
and all side branches were dissected free and excised. The skin was closed with a 
prolene monofilament (6-0) (Johnson & Johnson). 
 
Isolation of apoptotic exosome-like vesicles from murine serum 
Serum samples collected from mice pre surgery or 2 days post surgery 50 µL (to assay 
proteasome activity) or 25 µL (for western blot analyses) were diluted in 12 mL of RPMI 
and ultracentrifuged first at  50,000 xg for 15 min at 4ºC to pellet cell debris, apoptotic 
bodies and microparticles and after at 200,000 xg for 18 h at 4ºC to pellet exosome-like 
vesicles. After the last centrifugation, the pellets were resuspended in 2.4µl / µL of 
original serum sample in either PBS (to assay proteasome activity) or in Laemli buffer 
(for western blot analyses).  
 
 
Injection of murine apoptotic endothelial membrane vesicles  
Serum-free media conditioned by 1 x 104 murine endothelial cells were fractionated 
using sequential centrifugation: a first centrifugation 1200 x g for 15 min at 4ºC to pellet 
cell debris; a second centrifugation at 50 000 x g for 15 min at 4ºC to pellet apoptotic 
bodies and a final ultracentrifugation (200 000 x g for 18 h at 4ºC) to pellet exosome-like 
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vesicles. Pellets containing either apoptotic bodies or exosome-like vesicles were 
resuspended in half the initial volume of conditioned medium. Non-grafted or 
transplanted mice received tail vein (150 ul) IV injections of resuspended preparations 
every other day during three weeks for a total of 8 doses. In transplanted mice, the first 
injection occurred 2 days post-transplantation. 
 
Assessment of circulating levels of total IgGs, anti-nuclear antibodies (ANA) and 
anti-LG3 
Antinuclear antibodies and total IgG levels were assessed using ANA mouse bioassay 
kits (USBiologicals) and Mouse IgG total Ready-SET-Go kits (Affimetrix), respectively, 
in accordance with manufacturer’s instructions. Anti-LG3 titers were measured with a 
locally developed ELISA. Recombinant LG3 was produced and purified as previously 
described (78). Purity of the recovered LG3 protein was assessed by reducing SDS-
PAGE and Coomassie blue R250 staining. Recombinant mouse LG3 (10 ng/uL) was 
first coated on 96-well ImmulonII HB plates (Thermo Electron), for a total of 1ug per 
well. Notably, mouse and human LG3 fragments are highly (87%) homologous at the 
amino acid level. The sera were diluted (1:250), and 100 uL were added per well. The 
plates were washed, and bound IgG were detected using horseradish peroxidase 
coupled with anti-human or anti-mouse IgG (Amersham and Santa-Cruz respectively) or 
anti-IgG1, IgG2a, IgG2b, IgG3 for IgG subclasses studies(Santa-Cruz). Reactions were 
revealed with 100 uL of tetramethylbenzidine substrate (BD Biosciences) and stopped 
with 50 uL of sulfuric acid (H2SO4). Spectrophotometric analysis was taken at 450 nm 





Measurement of murine anti-donor IgG 
Sera were diluted 1:100 in FACS buffer and incubated with 1x 106 BALB/c splenocyte 
targets for 30 min at 4°C. The samples were then washed three times and stained with 
PE goat anti-mouse IgG (1:100, Alexa 488 anti-mouse CD3e, BD Biosciences) in FACS 
buffer for 30 min at 4°C, in the dark. Samples were run on a flow cytometer (FACScan, 
BD) and analyzed on computer software (FACS DIVA, Becton-Dickinson). CD3+ parent 
gate was utilized to avoid nonspecific background signal due to Fc receptor–expressing 
cells.  
 
Flow cytometry analyses for splenic germinal center B cells and follicular helper 
T cells 
Single-cell suspensions from the spleen were prepared and stained immediately for 
three-color flow cytometry. The percentage of CD4+PD-1+CXCR5+ Tfh cells among 
CD4+ cells was determined by flow cytometry using anti-programmed death-1(PD-1) 
FITC (eBioscience), anti-CXCR5 Biotin (BD biosciences), anti-CD8 APC (Biolegend), 
anti-CD4 PerCP (BD biosciences), anti-CD62L PE (BD biosciences), anti-CD44 Pacific 
blue (Biolegend) mAbs and Strep APC Cy7 (BD biosciences). The percentage of 
B220+GL7+Fas+ GC B cells among B220+ B cells was determined by flow cytometry 
using anti-B220 APC Cy7 (BD bioscience), anti-GL7 FITC (BD bioscience) and anti-Fas 





Transplanted and adjacent native aortas were harvested three weeks post-
transplantation. Tissues were fixed with 10% neutral buffered formalin and paraffin 
embedded according to established methods. Samples were cut into 4 μm slices. 
Immunohistochemistry was assessed on an immunostainer (Discovery XT system, 
Ventana Medical Systems, Tucson, AZ) in accordance with manufacturer’s 
recommendations. Antigen retrieval was performed with proprietary reagents. When 
mentioned, samples were stained with haematoxylin and eosin (H&E). For the detection 
of CD3+, F4/80 + cells and C4d deposition, indirect immunoperoxidase staining was 
performed using the primary  anti-CD3, anti-F4/80 antibody (1:50, AbD Serotec) or anti-
C4d (1:50, Biomedica), respectively, followed by incubation with specific secondary 
biotinylated antibodies. Streptavidin horseradish peroxidase and 3,3-diaminobenzidine 
were used according to the manufacturer’s instructions (DABmap detection kit, Ventana 
Medical Systems). Finally, sections were counterstained with hematoxylin. Digital 
images of tissues were captured by Leica DMLS microscope and Leica DFC420C 
camera (Leica Microsystems). Intimal and medial areas grafts were outlined and 
quantified using a digital image analysis program (ImageJ 1.42q, NIH). The presence of 
T cells and macrophages in the tissue were quantified by quantification of the number of 
CD3+ or F4/80+ cells respectively per 6 high power fields per allograft. C4d deposition 






All data are expressed as Means ± SEM derived from at least three independent 
experiments unless otherwise specified. Biological and histological data were compared 
using t test. Statistical analyses were performed using Prism 4 (Prism-GraphPad 





Supplementary figure 1. Serum deprivation significantly increased caspase-3 activation 
and the percentage of cells with chromatin condensation in absence of cell membrane 
permeabilization  
 
Supplementary figure 2. Small particle flow cytometry size calibration 
 
 
Supplementary figure 3. Characterization of small particles secreted by apoptotic 
endothelial cells sensitivity to detergent treatment 
 
Supplementary figure 4. Inhibition of autophagy with bafilomycin does not modulate 
exosome-like vesicle secretion by serum starved endothelial cells  
 
 
Supplementary figure 5. Electron micrographs of apoptotic bodies released by serum-
starved HUVECs and isolated by sequential ultracentrifugation  
 
Supplementary figure 6. Electron micrographs of exosome-like vesicles released by 




Supplementary figure 7. Gene ontology analysis of cellular components and biological 
processes for proteins unique to exosome-like vesicles and apoptotic bodies.  
 
 
Supplementary figure 8. Characterization of the presence of classical exosomal markers 
in the apoptotic exosome-like vesicles proteome  
 
Supplementary figure 9. Redundant peptide count of Perlecan in exosome-like vesicles 
and apoptotic bodies.  
. 
 
Supplementary figure 10.  Injecting equal amounts of proteins from preparations of 
apoptotic bodies and preparations of apoptotic exosome-like vesicles fail to unmask 
immunogenic activity in apoptotic bodies.  
 
 
Supplementary figure 11. Apoptotic exosome-like vesicles, unlike apoptotic bodies, 
favor B cell responses and autoimmunity  
 
Supplementary figure 12. Intima/media ratio in murine allografts 3, 6 or 9 weeks post-





Supplementary figure 13. Characterization of anti-LG3 IgG subclasses  
 
Supplementary figure 14. Healthy endothelial cells secrete exosome-size vesicles 
lacking caspase-like proteasome activity 
 
Supplementary figure 15. Apoptotic vascular smooth muscle cells and tubular epithelial 
cells also secrete active 20S proteasome in exosome-size extracellular vesicles  
 
Supplementary figure 16. Bortezomib treatment does not affect cell death levels  
 
Supplementary Figure 17. The proteasome is not detected in serum membrane vesicles 
isolated pre surgery.  
 
Supplementary table1. Quantitative proteomics identifications based on spectral 
counts in nanovesicles and apoptotic bodies from serum starved apoptotic HUVECS 
cells. 
 
Supplementary table 2. Quantitative proteomics identifications based on spectral 
counts in nanovesicles from serum starved apoptotic HUVECS cells treated with 
proteasome inhibitor bortezomib or vehicle 
 
Supplementary table 3. Ubiquitylated proteins identification by mass spectrometry in 
nanovesicles from serum starved HUVECS cells treated with proteasome inhibitor 
bortezomib or vehicle 
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Data S1: Source data, unedited gels 
Data S2: Source data, flow cytometry gating 
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Figure 1: Apoptotic endothelial cells secrete two discrete types of extracellular vesicles, apoptotic bodies 
and exosome-like vesicles, downstream of caspase- 3 activation.  
a) and b) Left panels: Representative FSC-PMT/SSC plots of the extracellular vesicles detected with fluorochrome-
conjugated annexin-V in the supernatant of serum-starved HUVECs exposed to vehicle, DEVD or ZVAD (a) or mECs 
from WT or Casp-3 KO mice (b). Two major subpopulations, named exosome-like vesicles (exo-like) and apoptotic 
bodies (apo bodies), are observed and 
gated. Triton panels represent annexin-V+ events detected in the supernatant after treatment with triton 0.05% (a) or 
mECs (b). Right panel: Flow cytometric quantifications of Annexin-V+ apoptotic bodies (white bars) and exosome-like 
vesicles (black bars) detected in the supernatant of HUVECs (a) or mECs (b). c) Electron micrographs of apoptotic 
bodies (left panel) and exosome-like vesicles (right panel) released by serumstarved HUVECs and isolated by 
sequential ultracentrifugation. d) Heatmap representation of protein abundance in isolated exosome-like 
vesicles and apoptotic bodies. Exosome-like vesicles and apoptotic bodies are characterized by distinct protein 
patterns. Perlecan is enriched in exosome-like vesicles, while several histones are unique to or enriched in apoptotic 
bodies. n≥6 for each condition. Data are pooled from 3 independent experiments. mean ± SEM, t-test. 
 
Figure 2. Apoptotic exosome-like vesicles are specifically enriched in Perlecan-LG3 fragment and trigger the 
production of anti-LG3 autoantibodies  
a) Sequence of the LG3 fragment and representation of identified peptides (red) in exosome-like vesicles and 
apoptotic bodies. The sequence coverage of LG3 is higher in exosome-like vesicles (59%) vs. apoptotic bodies 
(28%). b) Electron micrographs showing immunogold labeling for LG3 in exosome-like vesicles from serum starved 
HUVECs. Data are pooled from 3 independent experiments. c) 
Representative immunoblot and densitometry analysis for LG3 in exosome-like vesicles or apoptotic bodies purified 
from serum starved apoptotic HUVECs incubated with the pan-caspase inhibitor Z-VAD or vehicle. d) Representative 
immunoblot and densitometry analysis for LG3 in exosome-like vesicles or apoptotic bodies purified from serum 
starved apoptotic mECs from WT of Caspase-3 KO mice. e) Anti-LG3 IgG titers in sera from WT mice after 3 weeks 
of i.v. injections with vehicle, exosome-like vesicles or apoptotic bodies purified from serum starved murine 
endothelial cells. n≥6 for each condition, mean ± SEM, t-test. 
 
Figure 3. Apoptotic exosome-like vesicles aggravate vascular rejection.  
a) Anti-LG3 IgG titers in sera harvested 3 weeks post-surgery from allografted mice injected with vehicle, exosome-
like vesicles or apoptotic bodies for 3 weeks post-transplantation. b) H&E, CD3, CD20 and C4d stained aortic 
allograft sections from mice injected with vehicle, exosome-like vesicles or apoptotic bodies for 3 weeks post-
transplantation (top panels magnification: 5X, lower panels magnification: 20X). c) Intima/media ratio in allografts 
from mice injected with vehicle, exosome-like 
vesicles or apoptotic bodies for 3 weeks post-transplantation. d) Mean number of CD3 positive cells (T cells) per high 
power field in allografts from mice injected with vehicle, exosome-like vesicles or apoptotic bodies for 3 weeks post-
transplantation. e) Mean number of CD20 positive cells (B cells) per high power field in allografts from mice injected 
with vehicle, exosome-like vesicles or apoptotic bodies for 3 weeks posttransplantation. f) C4d deposition in allografts 
from mice injected with vehicle, exosome-like vesicles or apoptotic bodies for 3 weeks posttransplantation. g) Donor 
specific antibodies (DSA) levels in sera harvested 3 weeks post-surgery from allografted mice injected with vehicle, 
exosome-like vesicles or apoptotic bodies for 3 weeks post-transplantation. n≥8 for each condition. Data are pooled 
from 3 independent experiments. mean ± SEM, comparison with vehicle, t-test. 
 
Figure 4. The proteasome, active within apoptotic exosome-like vesicles, regulates the processing of various 
proteins, including LG3. 
a) Heatmap representation of proteasome protein abundance in exosome-like vesicles and apoptotic bodies. Lower 
panel: Western blot analysis for alpha 3 proteasome subunit in exosome-like vesicles (exo-like) and apoptotic bodies 
(apo bodies). b) Schematic representation of the proteins detected specifically in exosome-like vesicles (in red) and 
in apoptotic bodies (black). The complete proteasome 20S core complex is found in exosome-like vesicles while only 
regulatory subunits are detected in apoptotic bodies. c) Electron micrographs showing immunogold labeling of alpha 
3 proteasome subunit in exosome-like vesicles from serum starved HUVECs. d) Quantification of proteasome 
chymotrypsin, trypsin and caspase-like proteolytic activities in serum starved HUVECs (Grey bars), exosome-like 
vesicles (Black bars) and apoptotic bodies (White bars). n≥5 for each condition. mean ± SEM, comparison with cells 
e) Proteasome chymotrypsin, trypsin and caspase-like proteolytic activity quantification in exosome-like vesicles from 
serum starved HUVECS cells treated with the proteasome inhibitor bortezomib or its vehicle. mean ± SEM, 
comparison with vehicle f) Quantification, by flow cytometry, of Annexin-V+ EVs secreted by serum starved HUVEC 
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treated with the proteasome inhibitor bortezomib or vehicle. g) Heatmap representation of protein abundances in 
exosome-like vesicles from serum starved HUVECS cells treated with proteasome inhibitor bortezomib or vehicle. 
Bortezomib treatment strongly modulates the protein content of exosome-like vesicles. Perlecan is enriched in 
bortezomib-treated cells. h) LG3 spectral count in exosome-like vesicles from serum starved HUVECS treated with 
the proteasome inhibitor bortezomib or vehicle. i) Proteasome inhibition with Bortezomib results in the accumulation 
of ubiquitylated proteins in exosome-like vesicles. Upon bortezomib treatment 20 ubiquitylation sites on 19 proteins 
were detected, while in vehicle-treated control cells only 5 ubiquitinylation sites on 5 proteins were detected by mass 
spectrometry. mean ± SEM, , t-test, ns=nonsignificant. 
 
Figure 5. Proteasome activity within apoptotic exosome-like vesicles regulates anti-LG3 autoantibody 
formation and allograft inflammation.  
a) Anti-LG3 IgG titers in sera from WT (grey bars) or allografted mice (black bars) after 3 weeks of i.v. injections with 
vehicle, or with exosome-like vesicles from serum starved murine ECs treated with the proteasome inhibitor 
bortezomib (Exo-like Bortezo) or vehicle (Exolike Vehicle). b) CD3, CD20 and C4d stained aortic allograft sections 
from mice injected with exosome-like vesicles from serum starved murine ECs treated with bortezomib (Exo-like 
Bortezo) or vehicle (Exo-like Vehicle). (magnification: 20X ) c) Mean number of CD3 positive cells (T cells) per high 
power field in allografts from mice injected with exosome-like vesicles from serum starved murine ECs treated with 
bortezomib (Exo-like Bortezo) or vehicle (Exo-like Vehicle), for 3 weeks post-transplantation. d) Mean number of 
CD20 positive cells (B cells) per high power field in allografts from mice injected with exosome-like vesicles from 
serum starved murine ECs treated with bortezomib (Exo-like Bortezo) or vehicle (Exo-like Vehicle), for 3 weeks post-
transplantation. e) C4d deposition in allografts from mice injected with exosome-like vesicles from serum starved 
murine ECs treated with proteasome inhibitor bortezomib (Exo-like Bortezo) or vehicle (Exo-like Vehicle), for 3 weeks 
post-transplantation. n≥9 for each condition. Data are pooled from 4 independent experiments. mean ± SEM, if not 
indicated comparison with vehicle, t-test. 
 
Figure 6. Renal injury enhances circulating proteasome caspase-like activity, LG3 levels and anti-LG3 
production  
a) Blood urea nitrogen (BUN) concentration in mice pre-surgery or at 2, 7 or 21 days post-renal ischemia/ reperfusion 
(I/R) injury. b) Serum creatinine concentration in mice pre-surgery or at 2, 7 or 21 days post-renal I/R injury. c) 
Quantification of proteasome caspase-like activity in exosomelike vesicles from serum pre-surgery or 2 days post-
renal I/R injury. d) Serum anti-LG3 IgG titers pre-surgery or at 2, 7 14 and 21 days postrenal I/R injury e) 
Densitometry analyses of immunoblots for LG3 detection performed on exosome-like vesicles purified from serum of 
mice presurgery or 2 days post-renal I/R injury f) Representative Ponceau Red staining and immunoblot showing the 
detection of perlecan fragments, including LG3, in serum exosome-like vesicles pre surgery or 2 days post-renal I/R 
injury. g) Left panel: Electron micrographs of exosome-like vesicles isolated from serum 2 days post-renal ischemia-
reperfusion (I/R) injury. Right panels: Electron micrographs showing immunogold labeling for the alpha 3 
proteasome subunit in exosome-like vesicles isolated from serum 2 days post-renal ischemia-reperfusion (I/R) injury. 
from n=6 for each condition, mean ± SEM, comparison with pre-surgery. t-test. 
 
Figure 7. Vascular injury enhances circulating proteasome caspase-like activity, LG3 levels and anti-LG3 
production  
a) Laser Doppler imaging of blood flow in the lower limbs of mice on the day of the surgery (day 0) or at 7 or 21 days 
post femoral arteriectomy (vascular injury) b) Quantification of proteasome caspase-like activity in serum exosome-
like vesicles pre-surgery or 2 days post vascular injury c) Representative Ponceau Red staining and immunoblot 
showing the detection of perlecan fragments, including LG3, in serum exosome-like vesicles pre-surgery or 2 days 
post vascular injury. d) Densitometry analyses of immunoblots for LG3 detection performed on serum exosomelike 
vesicles pre surgery or 2 days post vascular injury. e) Serum anti-LG3 IgG titers pre-surgery or at 7, 14 and 21 days 
post vascular injury. n=6 for each condition, mean ± SEM, comparison with pre-surgery, t-test. 
